# US 2003/0232971 A1 · Tumour necrosis factor binding ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232971 A1
- Document ID: US20030232971A1
- Status: Published application
- Kind: A1
- Application number: 10/453,176
- Filed: 2003-06-02
- Published: 2003-12-18
- Earliest claimed: 1989-08-07
- Inventors: Deborah Ann Rathjen; Roger Aston
- Web page: https://patentgrep.com/patent/US20030232971A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.

## Claims

### Claim 1

A ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced.

### Claim 2

A ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the in vivo tumour regression activity of the TNF is enhanced; the ligand binding to the TNF such that the epitope of the TNF defined by the topographic region of residues 1-30, 117-128 and 141-153 is substantially prevented from binding to naturally occurring biologically active ligands.

### Claim 3

A ligand which binds to human TNF in the topographic regions of residues 1-30, 117-128 and 141-153.

### Claim 4 (depends on 3)

A ligand as claimed in claim 3 in which the ligand binds to human TNF in the topographic regions of residues 1-26, 117-128 and 141-153.

### Claim 5 (depends on 1)

A ligand as claimed in claim 1 in which the ligand is selected from the group consisting of antibodies, F(ab) fragments, single domain antibodies (dABs) restructured antibodies, single chain antibodies and serum binding proteins.

### Claim 6 (depends on 5)

A ligand as claimed in claim 5 in which the ligand is a monoclonal antibody or F(ab) fragment thereof.

### Claim 7 (depends on 1)

A ligand as claimed in claim 1 in which the ligand is MAb 32 (ECACC 89080302).

### Claim 8 (depends on 1)

A composition comprising TNF in combination with a ligand as claimed in claim 1 in which the ligand is bound to the TNF.
